Compare Illumina, Inc. (ILMN) vs VNET Group Inc (VNET) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs VNET Group Inc — how do they compare? Illumina, Inc. trades at $181.13 (market cap $27.94B), while VNET Group Inc trades at $7.75 (market cap $2.19B). The key difference: Illumina, Inc. is far larger — about 12.8× VNET Group Inc's market cap, and Illumina, Inc. is trading nearer its 52-week high, VNET Group Inc nearer its low. Which is the better fit depends on your goals.
| ILMN | VNET | |
|---|---|---|
Market Cap | $27.94B | $2.19B |
Sector | Health | Technology |
52-Week High | $194.33 | $14.03 |
52-Week Low | $91.00 | $7.34 |
Enterprise Value | $29.33B | $5.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
VNET Group trades at $7.675, up 3.86% today, but technical indicators signal a bearish trend with moving averages unanimously negative. The company reported a net loss of $256.77 million in 2025, with negative profit margins and ROE, though revenue grew to $9.95 billion. Recent news highlights strategic investments in AI and data center capacity, alongside a class action settlement announcement.
The outlook is mixed: analyst consensus is 62.5% buy with a 54% upside target, but persistent losses and bearish technicals pose risks. Investment opportunity hinges on execution of growth initiatives in AI-driven demand, while key risks include profitability challenges and competitive pressures in the data center market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →
